State Street Corp Aridis Pharmaceuticals, Inc. Transaction History

State Street Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.16 - $0.4 $25,440 - $63,600	159,000 Added 367.66%	202,247 $44,000
Q3 2022 Nov 15, 2022	BUY	$0.73 - $2.47 $11,096 - $37,544	15,200 Added 54.19%	43,247 $40,000
Q2 2022 Aug 15, 2022	BUY	$0.91 - $1.7 $1,456 - $2,720	1,600 Added 6.05%	28,047 $31,000
Q3 2021 Nov 15, 2021	BUY	$3.55 - $7.49 $93,886 - $198,088	26,447 New	26,447 $97,000

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.